Cargando…
The CD14(+)HLA-DR(lo/neg) Monocyte: An Immunosuppressive Phenotype That Restrains Responses to Cancer Immunotherapy
Recent successes in cancer immunotherapy have been tempered by sub-optimal clinical responses in the majority of patients. The impaired anti-tumor immune responses observed in these patients are likely a consequence of immune system dysfunction contributed to by a variety of factors that include, bu...
Autores principales: | Mengos, April E., Gastineau, Dennis A., Gustafson, Michael P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6540944/ https://www.ncbi.nlm.nih.gov/pubmed/31191529 http://dx.doi.org/10.3389/fimmu.2019.01147 |
Ejemplares similares
-
Expression profiling of suppressive monocytes (CD14+HLA-DRlow/neg) in cancer patients
por: Cordes, Stefan F, et al.
Publicado: (2013) -
Cancer Vaccines in the World of Immune Suppressive Monocytes (CD14(+)HLA-DR(lo/neg) Cells): The Gateway to Improved Responses
por: Laborde, Rebecca R., et al.
Publicado: (2014) -
Immune independent crosstalk between lymphoma and myeloid suppressor CD14(+)HLA-DR(low/neg) monocytes mediates chemotherapy resistance
por: Zhang, Zhe (Jenny), et al.
Publicado: (2015) -
Elevated frequencies of CD14(+)HLA-DR(lo/neg) MDSCs in COVID-19 patients
por: Xue, GuoHui, et al.
Publicado: (2021) -
Increased CTLA-4(+) T cells and an increased ratio of monocytes with loss of class II (CD14(+) HLA-DR(lo/neg)) found in aggressive pediatric sarcoma patients
por: Hingorani, Pooja, et al.
Publicado: (2015)